Dan Klass PhD

Dan earned his PhD in Biochemistry from Stanford University where he focused on developing new methods utilizing the latest in proteomic and genomic technologies in Pat Brown’s lab. As a postdoctoral scholar in the Oncology department at Stanford, he co-invented the CAPP-Seq technology for ctDNA NGS, and he has been working from within the Oncology Assay Development team to bring the technology to market ever since CAPP Medical was acquired by Roche Sequencing Solutions. He is currently designing the next generation of oncology assays and evaluating the potential oncology applications of new technologies.